Significant activity has been observed in
Haleon PLC in the bio-tech market. Major investors like
GSK and
Pfizer have sold substantial stakes in Haleon, with GSK offloading its entire stake, thus creating significant market movement. Pfizer's sell-off reduced its stake from 32% to 24%. Notably, Haleon has executed several strategic share
buyback programs, suggesting confident internal assessments. The buybacks, coupled with periodic profit increases, have pushed Haleon's share price to a new 52-week high. Furthermore, Haleon's first-half results revealed an 11% profit increase, suggesting decent fundamental health. The sale of its International NRT business, however, has sparked job cuts and the closure of its UK factory. One alarming note comes from Goldman Sachs, downgrading Haleon stock to 'Neutral' citing overvaluation. Despite these challenges, Haleon manages an active portfolio, showing solid EPS and profit growth in 2024 despite market challenges.
Haleon Stocks News Analytics from Thu, 05 Oct 2023 07:00:00 GMT to Sun, 25 Aug 2024 17:21:05 GMT -
Rating -2
- Innovation 5
- Information 6
- Rumor -6
